UBS tracks China's obesity drug R&D: orforglipron wins U.S. approval, China GLP-1 competition continues to heat up

Overview

This report is UBS's monthly tracker of obesity drug R&D and the competitive landscape in China's healthcare sector, with a focus on GLP-1, multi-target GLP-1/GIP, oral GLP-1, long-acting amylin, and related indication expansion. It also covers regulatory and clinical progress in China, global competitor data, and a later section that outlines monthly sales and the competitive landscape for China GLP-1 products.

Core views

The core message is that obesity drug development and commercialization competition are accelerating: Eli Lilly's oral small-molecule GLP-1 orforglipron has been approved in the United States and, in UBS's view, may be approved in China in 2027; Chinese domestic companies continue to advance in weight management and multi-target GLP-1/GIP pipelines, with Hansoh, CSPC, and United Lab all having important clinical or regulatory updates; and long-acting amylin, as a global next-generation weight-loss mechanism, is also rapidly accumulating data.

Analysis framework

The report uses a monthly event-tracking approach, organizing information across four dimensions: U.S. approvals, China approvals and clinical progress, global long-acting amylin data, and the competitive landscape for China GLP-1 products. It compares pipeline changes using efficacy, safety, indication, development stage, and commercialization investment.

Methodology notes

• Industry competition trackingMonthly tracking of the GLP-1 obesity drug competitive landscape

  Monitor changes in the obesity drug sector through approvals, clinical data, commercialization spending, and product sales progress.

  The report compares Chinese domestic candidates with global drugs sharing the same mechanism within one framework, and uses weight-loss magnitude, HbA1c changes, dosing frequency, tolerability, and regulatory progress to judge competitive positioning.

• Clinical data comparisonNon-head-to-head efficacy mapping

  Clinical trial results for different drugs are not directly head-to-head comparable.

  The report cites weight-loss data from multiple drugs across different trials, doses, and time points, so it is more suitable for directional observation rather than being read as a strict ranking of drug superiority.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China healthcare stocks

  Industry research coverage

  Strengths

  Innovative drug R&D progress is dense, and the GLP-1 and related obesity drug space is highly watched.

  Weaknesses

  Price negotiations, volume-based procurement, and intensifying competition may compress commercialization returns.

  Comparison

  Compared with traditional chronic-disease drugs, the obesity drug space is more clearly driven by differences in clinical efficacy, dosing convenience, and safety.

  Risks

  Policy-led price cuts, NRDL negotiation prices below expectations, tighter regulation, and geopolitical risk.

• GLP-1 and multi-target obesity drug pipelines

  Core industry asset

  Strengths

  Multiple companies have disclosed positive clinical or regulatory progress, and some candidates are showing relatively high weight-loss magnitudes.

  Weaknesses

  Trials are not directly head-to-head comparable, and long-term safety and commercialization durability still need validation.

  Comparison

  In the data cited in the report, Hansoh HS20094 shows a higher weight-loss magnitude and a better safety profile description than tirzepatide in China studies.

  Risks

  Crowded competition, pricing pressure, clinical failure, or regulatory delays.

• Long-acting amylin candidates

  Global competitors and next-generation mechanism reference

  Strengths

  Candidates such as petrelintide and ABBV-295 have disclosed positive weight-loss data, and dosing intervals offer room for differentiation.

  Weaknesses

  Some data are still in early or mid-stage development, with limited sample sizes and follow-up time.

  Comparison

  The report compares petrelintide and ABBV-295 with existing data from cagrilintide, eloralintide, and other programs for reference.

  Risks

  Later large-scale trials may disappoint on efficacy, or there may be tolerability issues or commercialization pressure.

Key data

• U.S. pricing for orforglipronUS$349/monthInitial U.S. cash DTC channel price; oral Wegovy is US$299/month.
• Prescriptions required for orforglipron 2026 revenueAbout 5.4m to 6m prescriptionsUBS U.S. pharma team estimates: about 5.4m prescriptions imply VA consensus revenue of US$1.7bn, and about 6m prescriptions imply UBSe revenue of US$2.0bn.
• Eli Lilly China investment planUS$3bn/10 yearsTo expand its supply chain in China with a focus on manufacturing oral GLP-1 orforglipron.
• Pharmaron-related investmentUS$200mEli Lilly plans to invest in building drug formulation capabilities and may have potential for capacity expansion.
• Ecnoglutide weight-loss data15.4% weight loss at 48 weeksSciwind's ecnoglutide has been approved in China for weight management.
• HS20094 weight-loss dataUp to 19.3% weight loss at 48 weeksHansoh GLP-1/GIP 15 mg phase III data; the report says gastrointestinal tolerability was good.
• tirzepatide China study reference17.5% weight loss at 52 weeksSURMOUNT-CN 15 mg data, used as a comparison reference for HS20094.
• UBT251 dataUp to 2.16% HbA1c reduction and 9.8% weight loss at 24 weeksUnited Lab and Novo published top-line phase II results in Chinese T2D patients.
• petrelintide dataUp to 10.7% weight loss at 42 weeksRoche and Zealand long-acting amylin phase II data; placebo was 1.7%.
• ABBV-295 dataUp to 9.79% weight loss at 12 weeksAbbVie long-acting amylin phase I data; weekly, biweekly, and monthly dosing were 9.79%, 7.76%, and 6.74%, respectively, versus 0.26% for placebo.

Impact & implications

For investment research, the report shows that China's obesity drug industry chain and innovative drug companies are facing denser product approvals, clinical readouts, and capacity deployment by global giants. If oral GLP-1 is approved in China, it could change patient access and commercialization pathways; if domestic GLP-1/GIP and related multi-target pipelines continue to show differentiated efficacy and tolerability, they may strengthen the competitiveness of Chinese innovative drugs in the weight-management market. At the same time, updates in long-acting amylin data suggest that the next generation of weight-loss mechanisms could become an important competitive direction after GLP-1.

Risks

• GPO price cuts are larger than expected.
• Industry competition intensifies.
• Prices after innovative drugs enter NRDL negotiations come in below expectations.
• China's consumption recovery is slower than expected.
• Regulatory announcements and enforcement are stricter than expected.
• Geopolitical tensions rise unexpectedly and affect company operations.
• Clinical trial data are not directly head-to-head comparable, which may lead to misinterpretation of efficacy differences by the market.

What to watch

• The NDA review progress for orforglipron in China for type 2 diabetes and weight-loss indications, and whether approval comes in 2027.
• The rollout pace of Eli Lilly's China supply chain and orforglipron formulation capability building.
• Hansoh HS20094's subsequent full phase III data, regulatory filing, and commercialization path.
• The clinical progress of CSPC's SYH2082 in China and the United States.
• The outcome of Novo's priority review for semaglutide for MASH in China.
• Monthly sales trends for China GLP-1 products and the domestic competitive landscape.
• Follow-up phase II and phase III data and safety performance for long-acting amylin candidates.